GlassScriptPhysician profile
Richard Thomas Lee
NPI 1770621575
$738.89
in general payments reported to CMS, 2019-2025
14 companies · $342 in 2025
The $342 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $29.85 · 2021: $25.32 · 2022: $164 · 2023: $69.81 · 2024: $108 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $426 · Education: $92.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $426.46 |
| Education | $92.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $165.23 | 2021-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $129.74 | 2020-2025 | Blenrep, Shingrix, Ojjaara |
| Janssen Biotech, INC. | $119.66 | 2022 | |
| Novartis Pharmaceuticals Corporation | $76.26 | 2025 | |
| Incyte Corporation | $50.66 | 2025 | Jakafi |
| Supreme Orthopedic Systems, LLC | $37.79 | 2024 | |
| Urovant Sciences INC | $30.92 | 2022 | |
| Janssen Pharmaceuticals, INC | $29.16 | 2024 | Xarelto |
| Beigene USA, INC. | $22.39 | 2024 | Tevimbra |
| Amneal Pharmaceuticals LLC | $19.08 | 2025 | Alymsys |
| Daiichi Sankyo INC. | $16.41 | 2023 | Injectafer |
| Sumitomo Pharma America, INC. | $14.86 | 2023 | Gemtesa |
| Celgene Corporation | $13.69 | 2025 | Reblozyl |
| Pfizer INC. | $13.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.